Tan, J.J.; Zhou, P.Y.; Lim, J.L.; Liu, F.; Kwa, L.H.A.
Optimising Regimen of Co-Amoxiclav (ORCA)—The Safety and Efficacy of Intravenous Co-Amoxiclav at Higher Dosing Frequency in Patients with Diabetic Foot Infection. Antibiotics 2025, 14, 758.
https://doi.org/10.3390/antibiotics14080758
AMA Style
Tan JJ, Zhou PY, Lim JL, Liu F, Kwa LHA.
Optimising Regimen of Co-Amoxiclav (ORCA)—The Safety and Efficacy of Intravenous Co-Amoxiclav at Higher Dosing Frequency in Patients with Diabetic Foot Infection. Antibiotics. 2025; 14(8):758.
https://doi.org/10.3390/antibiotics14080758
Chicago/Turabian Style
Tan, Jun Jie, Peijun Yvonne Zhou, Jia Le Lim, Fang Liu, and Lay Hoon Andrea Kwa.
2025. "Optimising Regimen of Co-Amoxiclav (ORCA)—The Safety and Efficacy of Intravenous Co-Amoxiclav at Higher Dosing Frequency in Patients with Diabetic Foot Infection" Antibiotics 14, no. 8: 758.
https://doi.org/10.3390/antibiotics14080758
APA Style
Tan, J. J., Zhou, P. Y., Lim, J. L., Liu, F., & Kwa, L. H. A.
(2025). Optimising Regimen of Co-Amoxiclav (ORCA)—The Safety and Efficacy of Intravenous Co-Amoxiclav at Higher Dosing Frequency in Patients with Diabetic Foot Infection. Antibiotics, 14(8), 758.
https://doi.org/10.3390/antibiotics14080758